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Background
So far, NI trials are almost exclusively performed in
phase III setting. However, the NI question might
already be relevant in phase II setting in several scenar-
ios, like: treatment optimization in diseases for which
standard treatments already exist, or investigation of
cytostatic agents, or rare diseases for which a phase III
trial will not be feasible, or try to establish a reduced
dose for frail patients. Before pursuing a phase III NI
trial, a phase II trial is warranted. If resources are lim-
ited, then the scale of the phase II trials might be con-
strained. Feasible design choices for small-scale phase II
trial with NI intention are desired.
Methods
Both frequentist hypothesis testing and confidence inter-
val (C.I.) approaches are considered for the intended NI
phase II trials. Both single-arm and two-arm trials with
a binary endpoint were performed, sample sizes
obtained from the two approaches are compared under
different parameter settings with the NI margin in the
hypothesis testing approach equal to the interval width
in the C.I. approach.
Results
If the success rate of standard treatment is 0.5, with the
NI margin 0.1 for the new treatment, the required sam-
ple size for one-sided hypothesis testing approach is at
least 283 patients in two-arm trial with power 80% and
20% type I error (alpha) and 158 in single-arm trial with
same power and 5% alpha. Using one-sided C.I.
approach with 95% confidence level and allowed width
of 0.1, only 76 patients are needed. The smaller the
margin or the width is, the larger sample size is needed
for either approach. The sample size from the C.I.
approach is always lower than that from the other
approach under the same settings.
Discussions
The approach of the hypothesis test here is basically the
same as for phase III trials, but could have a larger NI
margin or alpha [1,2]. However, the determination of
the NI margin is often problematic in a phase III setting
and even more difficult in phase II setting as reliable
previous data about the efficacy may not be available at
this early stage. The C.I. approach does not require the
NI margin or impose a rigid go/no-go decision rule only
based on the primary endpoint. This allows the investi-
gators to consider other aspects of the treatment for the
final decision, hence might be preferred.
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